Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 3:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 616 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo-Cohort 5 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of TAK-004 in Healthy Adults

NCT06236009
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-004, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 3, 2026, 3:01 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

NCT06643221
View directory record Official record
Conditions
Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy
Interventions
Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet
Behavioral · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2031
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 3, 2026, 3:01 PM EDT
Terminated Phase 2 Interventional Results available

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT02927080
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
ACE-083, ACE-083 or placebo
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

NCT00990613
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon IR, Dimebon Transdermal
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

NCT01294410
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Anti-IP-10 Antibody
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
La Jolla, California • Santa Monica, California • Wheat Ridge, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 3, 2026, 3:01 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of IGM-6268 in Healthy Volunteers

NCT05160402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IGM-6268, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

NCT01431898
View directory record Official record
Conditions
Hepatitis C
Interventions
GS-9669 tablets, Placebo to Match GS-9669 tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Los Angeles, California • DeLand, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 2 Interventional

Pleconaril Enteroviral Sepsis Syndrome

NCT00031512
View directory record Official record
Conditions
Enterovirus Infection
Interventions
Placebo, Pleconaril
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Days to 15 Days
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 3, 2026, 3:01 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

NCT05327816
View directory record Official record
Conditions
Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
Interventions
RSV preF-based Vaccine, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
11
States / cities
Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

NCT05642546
View directory record Official record
Conditions
Healthy
Interventions
NM8074, Placebo
Drug
Lead sponsor
NovelMed Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

NCT05731544
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
443 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
36
States / cities
Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

NCT02918929
View directory record Official record
Conditions
Presumptive NAFLD
Interventions
EDP 305, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

NCT05291091
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
12 Years to 50 Years · Male only
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of CTS21166 to Treat Alzheimer Disease

NCT00621010
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CTS21166 (ZPQ-21166)
Drug
Lead sponsor
CoMentis
Industry
Eligibility
22 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 9, 2008 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

NCT01591668
View directory record Official record
Conditions
Hepatitis C
Interventions
Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19

NCT04592549
View directory record Official record
Conditions
SARS-CoV-2
Interventions
ADM03820, Placebo
Drug · Other
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Winston-Salem, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants

NCT04605718
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RO7223280
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

NCT05824091
View directory record Official record
Conditions
Tuberculosis
Interventions
MK-7762 (TBD09), Placebo
Drug · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
19 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

NCT02676596
View directory record Official record
Conditions
Hyperlipidemia
Interventions
K-312 10 mg QD, K-312 25 mg QD, K-312 50 mg QD, K-312 100 mg QD, K-312 200 mg QD, K-312 400 mg QD, Placebo
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 3, 2026, 3:01 PM EDT
Active, not recruiting Phase 3 Interventional

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
123
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 3, 2026, 3:01 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT06610279
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-951, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

NCT02107872
View directory record Official record
Conditions
Metabolic Disorders
Interventions
REGN1500, placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 3, 2026, 3:01 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

NCT00151775
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Year to 16 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 3, 2026, 3:01 PM EDT